This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the current diagnostic landscape for Hepatitis C and the approval of Cepheid's Xpert HCV molecular test.

Ticker(s): DHR, Cepheid

Who's the expert?

Institution: PIH Health Downey Hospital

  • Gastroenterologist affiliated with Kaiser Permanente Fontana and Ontario Medical Centers. 
  • Currently manages 100+ patients with Hepatitis C
  • Clinical interest in MASH/NASH and Hepatitis 

Interview Questions
Q1.

Describe your background and practice setting

Added By: ben_admin
Q2.

How many Hepatitis C patients do you manage?

Added By: ben_admin
Q3.

What is the gold standard for a Hepatitis C diagnosis?

Added By: ben_admin
Q4.

What are your thoughts on the Xpert HCV molecular test?

Added By: ben_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.